Integrative Analysis of a Novel Eleven-Small Nucleolar RNA Prognostic Signature in Patients With Lower Grade Glioma.
The Cancer Genome Atlas
immune infiltration
lower grade glioma
molecular mechanism
small nucleolar RNA
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
01
2021
accepted:
12
05
2021
entrez:
24
6
2021
pubmed:
25
6
2021
medline:
25
6
2021
Statut:
epublish
Résumé
The present study used the RNA sequencing (RNA-seq) dataset to identify prognostic snoRNAs and construct a prognostic signature of The Cancer Genome Atla (TCGA) lower grade glioma (LGG) cohort, and comprehensive analysis of this signature. RNA-seq dataset of 488 patients from TCGA LGG cohort were included in this study. Comprehensive analysis including function enrichment, gene set enrichment analysis (GSEA), immune infiltration, cancer immune microenvironment, and connectivity map (CMap) were used to evaluate the snoRNAs prognostic signature. We identified 21 LGG prognostic snoRNAs and constructed a novel eleven-snoRNA prognostic signature for LGG patients. Survival analysis suggests that this signature is an independent prognostic risk factor for LGG, and the prognosis of LGG patients with a high-risk phenotype is poor (adjusted P = 0.003, adjusted hazard ratio = 2.076, 95% confidence interval = 1.290-3.340). GSEA and functional enrichment analysis suggest that this signature may be involved in the following biological processes and signaling pathways: such as cell cycle, Wnt, mitogen-activated protein kinase, janus kinase/signal transducer and activator of tran-ions, T cell receptor, nuclear factor-kappa B signaling pathway. CMap analysis screened out ten targeted therapy drugs for this signature: 15-delta prostaglandin J2, MG-262, vorinostat, 5155877, puromycin, anisomycin, withaferin A, ciclopirox, chloropyrazine and megestrol. We also found that high- and low-risk score phenotypes of LGG patients have significant differences in immune infiltration and cancer immune microenvironment. The present study identified a novel eleven-snoRNA prognostic signature of LGG and performed a integrative analysis of its molecular mechanisms and relationship with tumor immunity.
Identifiants
pubmed: 34164339
doi: 10.3389/fonc.2021.650828
pmc: PMC8215672
doi:
Types de publication
Journal Article
Langues
eng
Pagination
650828Informations de copyright
Copyright © 2021 Deng, Gong, Liao, Wang, Zhou, Zhu and Mo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncologist. 2018 Feb;23(2):157-e21
pubmed: 29133513
Cell. 2002 Apr 19;109(2):145-8
pubmed: 12007400
J Neurooncol. 2011 Nov;105(2):241-51
pubmed: 21598070
Behav Brain Res. 2001 Nov 1;125(1-2):279-84
pubmed: 11682119
Cancer Manag Res. 2018 Apr 13;10:787-803
pubmed: 29713196
Neoplasma. 2004;51(1):1-11
pubmed: 15004651
Nucleic Acids Res. 2019 Jan 8;47(D1):D1102-D1109
pubmed: 30371825
Nucleic Acids Res. 2016 Jan 4;44(D1):D380-4
pubmed: 26590256
Cancer Med. 2020 Oct;9(19):7018-7033
pubmed: 32780509
Biomed Res Int. 2016;2016:1634730
pubmed: 27069916
Onco Targets Ther. 2020 Nov 06;13:11397-11409
pubmed: 33192073
J Neurooncol. 2018 Apr;137(2):349-356
pubmed: 29264836
Int J Gynecol Cancer. 2017 Feb;27(2):258-266
pubmed: 27870712
Nat Rev Dis Primers. 2015 Jul 16;1:15017
pubmed: 27188790
Int J Mol Sci. 2019 Oct 25;20(21):
pubmed: 31731424
Neuro Oncol. 2018 Mar 27;20(4):546-556
pubmed: 29016887
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Nat Rev Cancer. 2007 Jan;7(1):54-60
pubmed: 17186018
J Cancer. 2019 Jun 2;10(14):3267-3283
pubmed: 31289599
Cancer Biol Ther. 2013 Feb;14(2):146-54
pubmed: 23192275
Sci Rep. 2015 Feb 26;5:8588
pubmed: 25715874
Nat Rev Dis Primers. 2017 Feb 23;3:17004
pubmed: 28230061
Afr J Tradit Complement Altern Med. 2017 Jan 13;14(2):319-324
pubmed: 28573248
Sci Rep. 2018 Jul 13;8(1):10668
pubmed: 30006566
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Histochem Cell Biol. 2020 Apr;153(4):257-269
pubmed: 32062699
Oncotarget. 2017 Jul 4;8(27):43953-43966
pubmed: 28410200
Onco Targets Ther. 2017 Sep 12;10:4493-4506
pubmed: 28979141
Biochimie. 2013 Apr;95(4):858-65
pubmed: 23261849
BMC Med Genomics. 2013 Sep 03;6:27
pubmed: 24004562
Int J Oncol. 2019 Dec;55(6):1296-1312
pubmed: 31638182
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Anticancer Drugs. 2017 Feb;28(2):180-186
pubmed: 27879498
Pathol Res Pract. 2019 Jun;215(6):152378
pubmed: 30871913
Neuro Oncol. 2012 Feb;14(2):215-21
pubmed: 22090453
J Cell Mol Med. 2020 Feb;24(3):2215-2228
pubmed: 31943775
Clin Cancer Res. 2012 Nov 1;18(21):6032-9
pubmed: 22923449
Oncol Rep. 2016 Apr;35(4):1916-24
pubmed: 26783004
Eur J Med Chem. 2017 Oct 20;139:325-336
pubmed: 28803047
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Invest New Drugs. 2013 Jun;31(3):545-57
pubmed: 23129310
Cell Prolif. 2020 Jan;53(1):e12706
pubmed: 31642559
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Clin Drug Investig. 2018 Oct;38(10):909-925
pubmed: 30097905
Invest New Drugs. 2014 Aug;32(4):604-17
pubmed: 24718901
J Clin Oncol. 2009 Apr 20;27(12):2052-8
pubmed: 19307505
Neuro Oncol. 2012 Jan;14(1):93-100
pubmed: 22028388
Genes Cancer. 2017 Mar;8(3-4):505-516
pubmed: 28680535
Semin Oncol. 1988 Apr;15(2 Suppl 1):3-13
pubmed: 3285483
Oncol Lett. 2018 Nov;16(5):6854-6860
pubmed: 30405829
Methods Mol Biol. 2018;1711:243-259
pubmed: 29344893
Acta Pharmacol Sin. 2012 Jul;33(7):935-40
pubmed: 22684030
J Neurooncol. 2017 Jan;131(2):201-211
pubmed: 27837436
Neoplasma. 2013;60(1):101-10
pubmed: 23067223
J Bioenerg Biomembr. 2017 Dec;49(6):437-443
pubmed: 29164469
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Cancer Cell Int. 2020 Jul 10;20:299
pubmed: 32669975
J Neurooncol. 2017 Sep;134(2):259-268
pubmed: 28681243
Biochem Biophys Res Commun. 2016 Sep 9;478(1):481-485
pubmed: 27404124
Biochem Biophys Res Commun. 2018 Nov 2;505(3):858-864
pubmed: 30301525
Nat Med. 2019 Dec;25(12):1873-1884
pubmed: 31806906
Biochim Biophys Acta. 1997 Nov 27;1359(2):174-80
pubmed: 9409814
Theranostics. 2019 Jul 28;9(19):5577-5594
pubmed: 31534504
Biochem Pharmacol. 2020 Mar;173:113602
pubmed: 31404528
Nat Commun. 2013;4:2612
pubmed: 24113773
Mol Carcinog. 2013 Feb;52(2):118-33
pubmed: 22086447
Biomolecules. 2019 Nov 02;9(11):
pubmed: 31684108
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Sci Rep. 2017 Oct 6;7(1):12754
pubmed: 28986550
BMC Genomics. 2015 Mar 28;16:250
pubmed: 25880556
J Nat Med. 2017 Jan;71(1):16-26
pubmed: 27372348
Science. 2006 Sep 29;313(5795):1929-35
pubmed: 17008526